Dianomi Therapeutics Inc, spun out of University of Wisconsin Madison, develops Mineral Coated Microparticle (MCM) technology aimed at improving efficacy and safety of treatments for inflammatory diseases. The company is focused on autoimmune diseases as well as partnering with biotech and pharmaceutical companies for additional applications. The technology mimics natural properties of mineralized tissues (bones, teeth) to preserve and control the release of small and large molecules, mRNA, and nucleic acids. This delivery system has longer sustained deliver capabilities than traditional systems such as polylactic-co-glycol acid (PLGA) or polyethylene glycol (PEG).
